Authors

Latest:

Women in Oncology: Leukemia Therapies in Humans, for Humans

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Nilofer Saba Azad, MD

Latest:

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Salman R. Punekar, MD

Latest:

Dr Punekar on the Evaluation of NT-112 in KRAS G12D+ Advanced Solid Tumors

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

Timothy Hughes, MD, MBBS, FRACP, FRCPA

Latest:

Dr Hughes on the Safety of Asciminib in Ph+ CP-CML

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.

Sameh Gaballa, MD (Associate Member, Division of Malignant Hematology at Moffitt Cancer Center)

Justin Moyers, MD

Latest:

Dr. Moyers on Real-World Data With Adjuvant Immunotherapy in Melanoma

Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.

Chad A. Hamilton, MD

Latest:

The Future of Ovarian Cancer Treatment

Oncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.

Sudeep Gupta, MBBS

Latest:

Dr. Gupta on the Use of Platinum Plus Standard Neoadjuvant Chemotherapy in TNBC

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.

Yasser Mohamed Ali Ged, MBBS

Latest:

Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCC

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

Tetsuya Mitsudomi, MD, PhD

Latest:

EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation

Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.

Jimmy Hwang, MD

Latest:

Dr. Hwang on First-line Treatment Options in HCC

Jimmy Hwang, MD, discusses currently available first-line treatment options in hepatocellular carcinoma, and areas of continued unmet need in this space.

Anna Barata, PhD

Latest:

Dr. Barata on Patient-Reported Toxicities With Axi-Cel at 1-Year of Follow-Up

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

David Miklos, MD

Latest:

Second-line Treatment Landscape in Relapsed/Refractory DLBCL

A concise discussion of second-line treatment options for DLBCL, focusing on preferred regimens for transplant-eligible and ineligible patients, and tailored approaches based on relapse timing.

Sakti Chakrabarti, MD

Latest:

Ongoing Research in GI Cancers

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.

Anthony Perissinotti, PharmD, BCOP

Latest:

Practical Advice on the Management of Tumor Lysis Syndrome

Closing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.

Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd

Latest:

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

Yardlee Kauffman, PharmD, MPH

Latest:

A New Generation of Cytokine-Based Immunotherapy Takes Shape

Nearly 40 years after the first cytokine-based therapy was approved for the treatment of patients with hairy cell leukemia, investigators are taking a fresh look at ways to leverage these signaling proteins to enhance immunotherapies and vaccines in other cancers.

Bo Wang, MD

Latest:

Find the Job That’s Right for You

The American Society of Clinical Oncology projects significant shortages of practicing oncologists compared with patients with new cancer diagnoses and existing cancer by 2025.

Jeffery Auletta, MD

Latest:

Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies

Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.

Matthew Lawrence Inra, MD

Latest:

Dr Inra on the Role of the Surgeon in Early-Stage Lung Cancer

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.